転移性腎細胞癌患者の治療におけるカムカム併用およびカムカムなしのニボルマブおよびイピリムマブ
転移性腎細胞癌の第一選択治療におけるカムカム併用およびカムカムなしのニボルマブとイピリムマブの併用
This phase I trial tests the safety, side effects, and best dose of camu camu when used in combination with nivolumab and ipilimumab in treating patients with kidney cancer that has spread to other places in the body. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Camu camu is a prebiotic that may have a beneficial effect on the immune system. Giving camu camu in combination with nivolumab and ipilimumab may kill more tumor cells than nivolumab and ipilimumab alone in patients with metastatic kidney cancer.
調査の概要
状態
詳細な説明
PRIMARY OBJECTIVE:
I. To determine the effect of camu camu in combination with nivolumab/ipilimumab on Ruminococcus abundance in stool samples of patients with metastatic renal cell carcinoma (mRCC).
SECONDARY OBJECTIVES:
I. To evaluate the effect of camu camu on the clinical efficacy of the nivolumab/ipilimumab combination.
II. To determine the effect of camu camu on systemic immunodulation of the nivolumab/ipilimumab combination in patients with mRCC.
III. To describe the toxicity and safety profile of the use of camu camu in combination with nivolumab/ipilimumab.
IV. To determine the effect of camu camu on gut microbiome diversity and function.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM 1: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for cycles 1-4. Beginning cycle 5, patients receive nivolumab over 30 minutes on day 1 of each cycle. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo blood and stool sample collection and undergo computed tomography (CT) and/or bone scan and/or magnetic resonance imaging (MRI) on trial.
ARM 2: Patients receive nivolumab IV over 30 minutes on day, ipilimumab IV over 30 minutes on day 1, and camu camu orally (PO) once a day (QD) continuously with each cycle. Cycles repeat every 3 weeks for cycles 1-4. Beginning cycle 5, patients receive nivolumab over 30 minutes on day 1, and camu camu PO QD of each cycle. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo blood and stool sample collection and undergo CT and/or bone scan and/or MRI on trial.
After completion of study treatment, patients are followed up every 12 weeks until time of death or formal withdrawal from the study, whichever comes first.
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
California
-
Duarte、California、アメリカ、91010
- City of Hope Medical Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Be willing and able to provide informed consent for the trial
-
Histological confirmation of renal cell carcinoma (RCC) with a clear-cell or sarcomatoid component
-
Advanced (not amenable to curative surgery or radiation therapy) or metastatic (American Joint Committee on Cancer [AJCC] 8 stage IV) RCC
-
Intermediate or poor risk disease by International Metastatic Renal Cell Carcinoma Database Consortium Criteria (IMDC) classification
-
No prior systemic therapy for RCC with the following exception:
- One prior adjuvant or neoadjuvant therapy for completely resectable RCC if such therapy did not include an agent that targets PD-1 or PD-L1 and if recurrence occurred at least 6 months after the last dose of adjuvant or neoadjuvant therapy
-
Eastern Cooperative Oncology Group (ECOG) performance status < 2
-
Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
-
Males and females, ages >= 18
-
Any ethnicity or race
-
Adequate renal function defined as calculated creatinine clearance >= 30 milliliters per minute (mL/min) per the Cockcroft and Gault formula or Serum creatinine < 1.5 x upper limit of normal (ULN)
-
Adequate liver function defined by aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x ULN (< 5 x ULN if liver metastases are present), and total bilirubin < 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin up to 3.0 mg/dL)
-
White blood cells (WBC) > 2,000/mm^3
-
Neutrophils > 1,500/mm^3
-
Platelets > 100,000/mm^3
Exclusion Criteria:
- Presence of untreated brain metastases. Patients with treated brain metastases must be stable for 4 weeks after completion of treatment and have documented stability on pre-study imaging. Patients must have no clinical symptoms from brain metastases and have no requirement for systemic corticosteroids amounting to > 10 mg/day of prednisone or its equivalent for at least 2 weeks prior to first dose of study drug. Patients with known leptomeningeal metastases are excluded, even if treated
- Favorable risk disease by IMDC classification
- Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
- Any active or recent history of a known or suspected autoimmune disease or recent history of a syndrome that required systemic corticosteroids (> 10 mg daily prednisone equivalent) or immunosuppressive medications except for syndromes which would not be expected to recur in the absence of an external trigger. Subjects with vitiligo or type I diabetes mellitus or residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement are permitted to enroll
- Active interstitial lung disease (ILD)/pneumonitis or history of ILD/pneumonitis requiring treatment with systemic steroids
- Baseline pulse oximetry less than 92% "on room air"
- Current use, or intent to use probiotics, prebiotics, yogurt, bacterial fortified foods and other natural supplements =< 2 week prior to treatment initiation and during the period of treatment
- Any condition requiring systemic treatment with corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to first dose of study drug. Inhaled steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
- Uncontrolled adrenal insufficiency
- Known medical condition (e.g., a condition associated with diarrhea or acute diverticulitis) that, in the investigator's opinion, would increase the risk associated with study participation or study drug administration or interfere with the interpretation of safety results
- Not recovered to =< Grade 1 toxicities related to any prior therapy before administration of study drug
- Women who are pregnant or breastfeeding
- History of myocarditis or congestive heart failure (as defined by New York Heart Association Functional Classification III or IV), as well as unstable angina, serious uncontrolled cardiac arrhythmia, uncontrolled infection, or myocardial infarction 6 months prior to study entry
- WBC < 2,000/mm^3
- Neutrophils < 1,500/mm^3
- Platelets < 100,000/mm^3
- AST or ALT > 3 x ULN (> 5 x ULN if liver metastases are present)
- Total bilirubin > 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin 3.0 mg/dL)
- Calculated creatinine clearance <30 millimeters per minute (mL/min) per the Cockcroft and Gault formula or serum creatinine > 1.5 x upper limit of normal (ULN)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Arm 1 (nivolumab and ipilimumab)
Patients receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for cycles 1-4. Beginning cycle 5, patients receive nivolumab over 30 minutes on day 1 of each cycle. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo blood and stool sample collection and undergo CT and/or bone scan and/or MRI on trial. |
Given IV
他の名前:
Undergo CT
他の名前:
Undergo MRI
他の名前:
Given IV
他の名前:
Undergo bone scan
他の名前:
Undergo blood and stool sample collection
他の名前:
|
|
実験的:Arm 2 (nivolumab, ipilimumab, camu camu)
Patients receive nivolumab IV over 30 minutes on day, ipilimumab IV over 30 minutes on day 1, and camu camu PO QD continuously with each cycle. Cycles repeat every 3 weeks for cycles 1-4. Beginning cycle 5, patients receive nivolumab over 30 minutes on day 1, and camu camu PO QD of each cycle. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo blood and stool sample collection and undergo CT and/or bone scan and/or MRI on trial. |
Given IV
他の名前:
Undergo CT
他の名前:
Undergo MRI
他の名前:
Given IV
他の名前:
Undergo bone scan
他の名前:
Undergo blood and stool sample collection
他の名前:
Given PO
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Abundance of ruminococcus in the stool
時間枠:From baseline to week 12 of therapy
|
Using a two-group t-test with a one-sided type I error of 0.05. |
From baseline to week 12 of therapy
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Best overall response
時間枠:Every 12 weeks for up to 3 years
|
Response and progression will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Will be examined using Fisher's exact test. |
Every 12 weeks for up to 3 years
|
|
Progression-free survival (PFS)
時間枠:Time from enrollment to progression date or date of death, whichever occurs first (Each cycle is 4 weeks)
|
PFS, assessed as the duration of time from enrollment to progression, with camu camu in combination with nivolumab/ipilimumab vs nivolumab/ipilimumab alone. The difference in progression-free survival across the two groups will be explored graphically using Kaplan-Meier survival plots. Median progression-free survival time for each of the two arms will be reported and Cox Proportional Hazards model will be used to estimate the hazard ratio and its confidence interval. |
Time from enrollment to progression date or date of death, whichever occurs first (Each cycle is 4 weeks)
|
|
Incidence of adverse events
時間枠:Up to 30 days post-last dose of protocol therapy
|
Will perform statistical analysis to compare the rates of all grade and grade >= 3 (per Common Terminology Criteria for Adverse Events version 5) treatment related adverse events between nivolumab/ipilimumab and nivolumab/ipilimumab with camu camu arms. |
Up to 30 days post-last dose of protocol therapy
|
協力者と研究者
捜査官
- 主任研究者:Sumanta K Pal、City of Hope Medical Center
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 泌尿生殖器疾患
- 泌尿生殖器腫瘍
- 部位別新生物
- 新生物
- 男性の泌尿生殖器疾患
- 腎臓病
- 泌尿器疾患
- 女性の泌尿生殖器疾患
- 女性の泌尿生殖器疾患と妊娠合併症
- 組織型別の新生物
- 新生物、腺および上皮
- 腺癌
- 泌尿器科の新生物
- がん
- 腎腫瘍
- がん、腎細胞
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 調査手法
- 臨床検査技術
- 診断技術と手順
- 診断
- 生物学的要因
- 抗体、モノクローナル、ヒト化
- 抗体、モノクローナル
- 抗体
- 免疫グロブリン
- 免疫タンパク質
- 血液タンパク質
- 血清グロブリン
- グロブリン
- 化学技術、分析
- スペクトル分析
- 受容体、細胞表面
- 膜タンパク質
- 抗原
- 抗原、表面
- バイオマーカー
- 受容体、免疫学的
- 抗原、分化、Tリンパ球
- 抗原、分化
- 免疫チェックポイントタンパク質
- 共刺激および阻害性T細胞受容体
- ニボルマブ
- イピリムマブ
- 標本処理
- 磁気共鳴分光法
- CTLA-4抗原
その他の研究ID番号
- 22457
- P30CA033572 (米国 NIH グラント/契約)
- 22457 (その他の識別子:City of Hope Medical Center)
- NCI-2023-06703 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。